Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Antios Therapeutics

http://www.antiostherapeutics.com

Latest From Antios Therapeutics

Antios Raises $96m To Advance HBV Drug With Pharmasset Pedigree

Antios thinks ATI-2173, which employs the Pharmasset liver-targeting chemistry used in HCV blockbuster Sovaldi, can help produce a functional cure in hepatitis B combination therapy.

Financing Business Strategies

Finance Watch: Alternative Funding Sources Crucial Even Amidst A Biopharma VC Boom

Private Company Edition: Investments by CIRM, the GHIT fund and the European Investment Bank back early-stage science and treatments for neglected diseases. Also, Versant Ventures raises $700m in two funds. In VC deals, Akero raised $70m, Impel NeuroPharma brought in $67.5m.

Financing StartUps and SMEs
See All

Company Information

  • Industry
  • Biotechnology
  • Diversified
  • Pharmaceuticals
  • Pharmaceuticals
    • Chiral Chemistry
  • Biotechnology
    • Antisense, Oligonucleotides
    • Large Molecule
    • Liposomes
    • Nanotechnology, Chips, etc.
    • Pharmacogenetics-Pharmacogenomics
    • Synthesis Technologies, Production Processes
    • Transgenics
    • Large Molecule
      • Antibodies
    • Drug Discovery Tools
      • Bioinformatics
      • Molecular Diversity
UsernamePublicRestriction

Register